1662 results for "LSD"
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Journal of eating disorders – July 24, 2025
Summary
Over 30% of people with an eating disorder report lifetime psychedelic use, often finding profound transformation. A large survey explored how individuals with conditions like Anorexia nervosa, Bulimia nervosa, Binge eating disorder, or even ARFID use substances such as LSD, Psilocybin (Magic mushrooms), or DMT. Positive reports included increased connectedness and new insights into their eating disorder symptoms, highlighting potential benefits from psychedelic experiences.
Abstract
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating...
The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.
Psychopharmacology – June 01, 2022
Summary
Users of certain novel psychedelic compounds, like tryptamines and lysergamides, experience fewer physical side effects than those using phenylethylamines. Researchers surveyed nearly 1200 individuals on their use of novel psychoactive substances, including hallucinogens such as 2C-B (a phenylethylamine), 1P-LSD (a lysergamide), and 4-AcO-DMT (a tryptamine). Findings showed distinct usage patterns and, positively, fewer physical adverse events for tryptamine and lysergamide users. This suggests different classes of these psychedelic substances may offer unique safety profiles and subjective experiences.
Abstract
Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unli...
History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Journal of psychoactive drugs – January 01, 2014
Summary
Born from a 1980s vision that psychedelics could aid humanity, one organization pioneered rigorous MDMA-assisted therapy for PTSD. They achieved positive results in the first double-blind, placebo-controlled trials, with FDA approval planned. Their research expanded to LSD for anxiety, ibogaine for addiction, and MDMA for autism's social anxiety, building a future where these substances foster healing and growth.
Abstract
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future...
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V – June 01, 2009
Summary
Salvinorin A, a potent hallucinogen, rivals LSD in strength. Research explored how the body handles this unique compound. Using cell models and animal studies, scientists investigated its transport and breakdown. Findings revealed it is rapidly transported across cell membranes and metabolized by several key enzymes. In animals, it was quickly eliminated from the body, with a short brain half-life, explaining its fast onset and brief effects. This clarifies the mechanisms behind its potent, fleeting action.
Abstract
Salvinorin A is an unregulated potent hallucinogen isolated from the leaves of Salvia divinorum. It is the only known non-nitrogenous kappa-opioid ...
Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry.
Rapid communications in mass spectrometry : RCM – January 01, 2006
Summary
Salvinorin A, a naturally occurring hallucinogen rivalling LSD in potency, is a key compound in Diviner's sage. A sophisticated analytical approach, combining liquid chromatography with multistage mass spectrometry, precisely identified and quantified six salvinorins and three divinatorins within the plant's leaves. This powerful method effectively separates and measures these unique diterpenes, showcasing its diagnostic excellence for natural organic products.
Abstract
Salvinorin A is the most potent naturally occurring hallucinogen known and rivals synthetic LSD in potency. Structurally it belongs to the neoclero...
Bufotenine: toward an understanding of possible psychoactive mechanisms.
Journal of psychoactive drugs – January 01, 2000
Summary
Bufotenine, a compound chemically similar to LSD, actively binds to brain receptors linked to hallucinogenic effects. Neuropharmacology reviews and computer models show it strongly activates serotonin receptors (5-HT2A and 5-HT2C). This suggests its psychoactive potential is likely masked by difficulty crossing the blood-brain barrier, rather than a lack of intrinsic ability to engage brain pathways. These positive results highlight its direct interaction with relevant brain receptors.
Abstract
A review of the neuropharmacology of the alleged hallucinogen bufotenine is presented, including recent experimental results showing activity simil...
Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine.
Psychopharmacology – January 01, 1987
Summary
Male Wistar rats trained to recognize the effects of 5-OMe-DMT demonstrated significant drug generalization, with LSD showing the highest potency (ED50 of 0.04 mg/kg). Other notable drugs included 8-OH-DPAT (0.11 mg/kg) and BAY R 1531 (0.15 mg/kg). The effectiveness of these drugs correlated strongly with their binding affinity for the 5-HT1A serotonin receptor. In contrast, several compounds, including citalopram and methysergide, did not generalize effectively, underscoring the critical role of the 5-HT1A receptor in mediating 5-OMe-DMT's interoceptive effects.
Abstract
Male Wistar rats were trained to discriminate the interoceptive effects of 5-methoxy-N,N-dimethyltryptamine (5-OMe-DMT; 1.25 mg/kg, IP) from saline...
Raphe neurons: firing rate correlates with size of drug response.
European journal of pharmacology – June 03, 1983
Summary
Higher spontaneous discharge rates in serotonergic neurons are linked to weaker responses to hallucinogenic drugs like 5-MeODMT and LSD. In a study involving unanesthetized cats, significant negative correlations were observed in key brain areas, including the dorsal raphe nucleus. Specifically, as the discharge rate increased, the response magnitude to these drugs decreased. This suggests that autoreceptor density may play a crucial role in regulating neuron activity and responsiveness to serotonin agonists, highlighting a complex interaction within the brain's serotonin system.
Abstract
Significant negative correlations were obtained between the spontaneous discharge rate during waking and the neural response to systemic injections...
High-affinity 3H-serotonin binding to caudate: inhibition by hallucinogens and serotoninergic drugs.
Psychopharmacology – September 15, 1978
Summary
Specific binding of 3H-serotonin to calf caudate homogenate reveals a dissociation constant of 2nM and 14 femtomoles of specific sites per milligram of protein. Notably, serotonin agonists and antagonists predominantly inhibit this binding. For instance, bufotenin inhibits at 6nM, while LSD requires 9.5nM for a similar effect. Other notable concentrations include 12nM for 5-methoxytryptamine and 16nM for methysergide. These findings highlight the potency of various serotonergic compounds in modulating serotonin binding, with implications for understanding neurotransmitter interactions.
Abstract
The specific binding of 3H-serotonin to calf caudate homogenate was studied. The dissociation constant was 2nM and the number of specific sites was...
Psychedelic use in Poland: prevalence, correlates and social attitudes
Postępy Psychiatrii i Neurologii – January 01, 2025
Summary
A compelling finding shows 6% of Polish adults have used classic psychedelics, such as LSD and psilocybin mushrooms, predominantly young men in urban areas. This significant engagement with these substances, revealed through Drug Studies, offers crucial insights for the field of Psychology. Understanding these usage patterns is vital for advancing the scientific exploration of Psychedelic-Assisted Therapy. Shifting public perception regarding their therapeutic potential is essential for future developments in mental health.
Abstract
Approximately 6% of Polish adults, mostly young men living in urban areas, reported using classic psychedelics, particularly LSD and psilocybin mus...
The history of ergot of rye (Claviceps purpurea) III: 1940-80.
The journal of the Royal College of Physicians of Edinburgh – March 01, 2010
Summary
The 1940-80 period revealed ergot's profound medical potential. While early hopes for LSD as a psychiatric treatment proved disappointing, another derivative, bromocriptine, revolutionized neuroscience. It dramatically advanced understanding of dopamine receptors, becoming a crucial therapy for Parkinson's disease, prolactinomas, and lactation suppression—a significant medical triumph.
Abstract
The period 1940-80 in the history of ergot was dominated by two investigators, Arthur Stoll and Albert Hofmann. There was great excitement when the...
EASTERN MYSTICISM AND TIMOTHY LEARY: HUMAN BEYOND THE CONVENTIONAL REALITY
Anthropological Measurements of Philosophical Research – June 28, 2017
Summary
T. Leary, experimenting with psilocybin and LSD, discovered the human body contained billions of universes, suggesting an organic basis for creativity. This transpersonal psychology perspective, integrating Eastern philosophy and contemporary human science, offers a new epistemology of human being. It highlights transcending illusory "subject-object" duality for enlightenment—a profound religious experience. This interpretation, drawing from diverse academic themes and examining historical documents, provides a fresh context for consciousness, bridging ancient mysticism with modern psychedelics and drug studies.
Abstract
Introduction. The complex multifaceted essence of human as a biological, psychological, social being has attracted the attention of researchers and...
Animal Models of Serotonergic Psychedelics
ACS Chemical Neuroscience – September 24, 2012
Summary
Neuroscience reveals that even rodent models exhibit behavioral changes mirroring human responses to Serotonergic hallucinogens like Psilocybin, Lysergic acid diethylamide (LSD), and Mescaline. This challenges assumptions about the uniquely human effects on Cognition and emotion. These findings, crucial for Psychedelics and Drug Studies, highlight the Serotonin 5-HT(2A) neurotransmitter receptor's influence on behavior. Understanding these molecular mechanisms and neuronal circuits through biochemical analysis and sensing techniques offers significant translational potential for Psychology.
Abstract
The serotonin 5-HT(2A) receptor is the major target of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Serot...
4 Psychedelics: therapeutic mechanisms
Journal of Neurology Neurosurgery & Psychiatry – July 20, 2020
Summary
Psychedelics like Psilocybin are profoundly reshaping our understanding of mental health. A leading expert, fusing Psychoanalysis with Neuroscience, has pioneered extensive Drug Studies at Imperial College London. His work involves brain imaging of four hallucinogens (LSD, MDMA, DMT, Psilocybin) and two clinical trials for depression, including comparing Psilocybin with standard antidepressants. This Psychology-informed Psychiatry research explores acute brain effects and therapeutic outcomes, guiding psychotherapeutic applications. Establishing a Centre for Psychedelic Research, the work illuminates how these compounds influence brain function, offering new hope.
Abstract
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA ...
The role and basis of the drug laws
Prometheus – September 01, 2010
Summary
Did you know some illegal drugs like ecstasy and LSD are scientifically shown to be less harmful than alcohol? Research reveals a significant gap between public perception and the actual risks of substances, even suggesting ecstasy is less dangerous than horse riding. This crucial insight challenges existing drug classifications, advocating for policies grounded in objective harm assessment rather than outdated assumptions.
Abstract
On 30 October 2009, the home secretary in the UK asked David Nutt to resign from his post as chairman of the government's advisory council on the m...
Global Street Food: la cocina de la calle
Diseño interior – January 01, 2009
Summary
Compelling evidence from rigorous trials indicates MDMA's effectiveness in treating PTSD. Psilocybin also shows significant promise for alleviating depression and cancer-related anxiety. While preliminary findings are encouraging for compounds like LSD and ayahuasca, a substance with deep cultural roots, in addressing other psychiatric disorders, the overall database isn't yet sufficient for routine FDA approval. Continued investigation into these compounds is warranted.
Abstract
Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related a...
Use of psilocybin (“mushrooms”) among US adults: 2015–2018
Journal of Psychedelic Studies – February 04, 2021
Summary
Nearly two-thirds of individuals who have used Lysergic acid diethylamide (LSD), methamphetamine, or Heroin also reported using Psilocybin. A national survey of 168,650 US adults revealed 9.68% lifetime use of this Hallucinogen. Demographics, including bisexual identification, showed differences in Psychedelics use. Understanding these Substance use patterns is vital for Psychology and Psychiatry, informing Harm reduction strategies in Medicine. This Demography data contributes to Psychedelics and Drug Studies, highlighting complex Behavior and Sexuality links.
Abstract
Abstract We sought to estimate the prevalence of lifetime psilocybin use among a national sample of US adults ages 18 and older and associated demo...
Over 30 million psychedelic users in the United States
F1000Research – March 28, 2013
Summary
Approximately 32 million Americans had used psychedelics like chemically synthesized LSD or psilocybin, from plant biology, by 2010. A 2010 US population survey of 57,873 individuals revealed 17% of those aged 21-64 years had lifetime psychedelic experience, including 22% of males and 12% of females. Use was highest among 30-34 year olds, with 20% reporting use (26% males, 15% females), informing diverse academic research themes within drug studies.
Abstract
We estimated lifetime prevalence of psychedelic use (lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), mescaline, and peyote) by age ...
Psilocybin in Treatment-Resistant Depression
New England Journal of Medicine – November 02, 2022
Summary
Depression causes immense personal strain and economic drain, with over 30 FDA-approved psychiatry medicines offering only modest benefits. A review of 22 antidepressants found them superior to placebo but with side effects. Consequently, pharmacology is revisiting hallucinogens like psilocybin and lysergic acid diethylamide (LSD) as potential new medicine. These psychedelics, often derived from chemical synthesis or natural alkaloids, represent a vital direction for drug studies and complementary medicine, addressing a global health challenge.
Abstract
Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic dr...
Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews – June 01, 2013
Summary
Classic hallucinogens like psilocybin and lysergic acid diethylamide (LSD) show renewed promise for addiction treatment. A compelling finding is the re-evaluation of older literature, alongside new insights from Psychedelics and Drug Studies, highlighting their therapeutic potential. This involves understanding their Neurotransmitter Receptor Influence on Behavior, stemming from their unique chemical synthesis and alkaloids. Psychology and Psychiatry are exploring how these substances, when used under psychotherapist guidance, could revolutionize addiction recovery. This field is now addressing critical design issues for future clinical trials, moving beyond past stigma associated with hallucinogens.
Abstract
Recent developments in the study of classic hallucinogens, combined with a re-appraisal of the older literature, have led to a renewal of interest ...
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
Journal of Psychopharmacology – January 01, 2022
Summary
Remarkably, in an analysis of 484,732 adults, lifetime MDMA (Ecstasy) use correlated with 10% reduced odds of past year suicidal ideation and planning. Psilocybin, a hallucinogen, showed 22% reduced odds of past month psychological distress and 10% reduced odds of suicidal thinking. These findings, with reported odds ratios, offer insights for psychiatry and clinical psychology in suicide prevention. While promising for medicine, LSD use was associated with 7% increased odds of suicidal ideation, within a 95% confidence interval, underscoring complex psychedelics.
Abstract
Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence,...
Structure-based discovery of nonhallucinogenic psychedelic analogs
Science – January 27, 2022
Summary
A breakthrough in pharmacology reveals a path to safer therapies, creating non-hallucinogenic compounds with antidepressant potential. By mapping how Lysergic acid diethylamide (LSD) and psilocin, a psilocybin metabolite, interact with the brain's 5-HT receptor, neuroscience advances. Crucially, serotonin and psilocin exhibit a unique second binding mode. This chemical understanding, vital for drug studies and chemical synthesis, allowed the design of new psychedelics. These compounds, influencing neurotransmitter receptor behavior, showed antidepressant-like activity in mice without hallucinogenic effects, promising targeted treatments for the serotonin receptor.
Abstract
Drugs that target the human serotonin 2A receptor (5-HT 2A R) are used to treat neuropsychiatric diseases; however, many have hallucinogenic effect...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
Can psychedelics have a role in psychiatry once again?
The British Journal of Psychiatry – June 01, 2005
Summary
Ancient wisdom meets modern science: Hallucinogens like Mescaline (a Phenethylamine), Psilocybin, and Lysergic acid derivatives such as Lysergic acid diethylamide (LSD) have been used for thousands of years. Contemporary Psychology and Psychedelics and Drug Studies now investigate their profound Neurotransmitter Receptor Influence on Behavior, with MDMA showing promise for Treatment of Major Depression. This field explores their therapeutic potential and mechanisms.
Abstract
Psychedelic or hallucinogenic drugs such as lysergic acid diethylamide (LSD), 3, 4, 5-trimethoxy-β-phenethylamine (mescaline), psilocybin, 3, 4-met...
A review of psilocybin: chemistry, clinical uses and future research directions
Australian Journal of Chemistry – May 16, 2023
Summary
Public interest in psychedelics like Psilocybin and Lysergic acid diethylamide (LSD) for mental health is soaring, yet robust clinical evidence for their benefits is still developing. These classic hallucinogens, functioning via specific serotonin receptor pharmacology, are being rigorously examined. Psilocybin, a tryptophan-based alkaloid found naturally, is a key focus. Current drug studies are evaluating its chemistry and proposed therapeutic mechanisms for Psychiatry. This review synthesizes the existing evidence base, guiding future chemical synthesis and psychological applications.
Abstract
Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individua...
Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research
Pharmacopsychiatry – July 01, 1998
Summary
The pharmacology of hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin profoundly impacts neurotransmitter systems, offering critical neuroscience insights. Research demonstrates that drug-induced psychosis, and potentially conditions like schizophrenia, involve a complex mechanism of multiple interactive neurotransmitter receptors. Specifically, a dysbalance among three key neurotransmitters—serotonin, glutamate, and dopamine—influences behavior. These psychedelics and dissociative drug studies provide powerful tools for psychology, elucidating neuropsychiatric disorder pathophysiology. Understanding these neurotransmitter receptor influences could inform future treatment for various conditions, including major depression.
Abstract
Recent research into the pharmacological mechanism of hallucinogens (LSD, psilocybin) and dissociative anesthetics (PCP, ketamine) suggest that mul...
A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
Journal of Psychoactive Drugs – June 12, 2020
Summary
Psychedelic-assisted therapy shows remarkable promise, with nine randomized controlled clinical trials revealing an impressive effect size of 1.21, exceeding typical psychopharmacological interventions. These clinical trials, a resurgence in drug studies for medicine and psychiatry, examined hallucinogens like psilocybin, LSD, and ayahuasca (containing N,N-dimethyltryptamine and harmala monoamine oxidase inhibitor alkaloids). Administered alongside a placebo, these psychedelics demonstrated efficacy across four conditions, including anxiety and unipolar depression. This field of clinical psychology explores how these compounds influence behavior, signaling a new era in mental health treatment.
Abstract
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted ther...
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
ACS Chemical Neuroscience – July 23, 2018
Summary
N, N-dimethyltryptamine (DMT), a potent hallucinogen, is remarkably ubiquitous, produced by diverse plant and animal species, and even endogenously in mammals. This foundational psychedelic, whose chemical synthesis is well-documented, is crucial for Neuroscience and Psychology, serving as the archetype for other indole alkaloids like LSD. Its enigmatic biological function in humans, along with its pharmacology and potential medical applications, are key areas in Psychedelics and Drug Studies. Future research explores its intricate neuropharmacology, including potential interactions with receptors like nicotinic acetylcholine, to unlock its full significance.
Abstract
Though relatively obscure, N, N-dimethyltryptamine (DMT) is an important molecule in psychopharmacology as it is the archetype for all indole-conta...
The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review
Frontiers in Psychiatry – November 20, 2017
Summary
Hallucinogen-persisting perception disorder (HPPD), a syndrome causing prolonged visual disturbances reminiscent of acute drug effects, was only established as a formal diagnosis in 2000, despite being described in 1954. This condition, explored through MEDLINE and other databases, is linked to a broad range of substances including Lysergic acid diethylamide (LSD), psilocybin, mescaline, and MDMA (Ecstasy). Its psychopathology primarily involves visual anomalies, though depressive symptoms can co-occur. Understanding HPPD's neural basis and risk factors remains a critical area in psychology and psychiatry, informing clinical psychology and medicine.
Abstract
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acut...
Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice
Journal of Humanistic Psychology – June 23, 2021
Summary
To effectively guide patients, psychotherapists administering psilocybin-assisted therapy may benefit from experiencing this hallucinogen. Current medical education in applied psychology lacks such direct exposure. Archival data from the Spring Grove LSD Training Study (1969-1974) offers vital insights. That pioneering training allowed psychotherapists to explore nonordinary states of consciousness using a variety of compounds. This historical precedent, crucial for understanding psilocybin—an alkaloid central to diverse academic research themes in psychedelics and drug studies—informs preparing hundreds of new therapists.
Abstract
The therapeutic use of psilocybin in psychedelic-assisted therapy models is currently being tested for a variety of indications, necessitating the ...
Associations between classic psychedelics and nicotine dependence in a nationally representative sample
Scientific Reports – June 22, 2022
Summary
Lifetime psilocybin use is linked to reduced odds of nicotine dependence. A large psychology study of 214,505 adults found psilocybin use was associated with 7-13% lower odds of current nicotine dependence. Mescaline and peyote also showed 9-21% reduced odds of specific nicotine dependence measures. However, LSD use was associated with 17-24% *increased* odds. This logistic regression analysis suggests certain hallucinogen psychedelics might offer new avenues in medicine and psychiatry for addiction and smoking cessation, influencing nicotinic acetylcholine receptors. This field of drug studies explores novel approaches to addiction.
Abstract
Abstract Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation ...
"MODEL PSYCHOSIS" PRODUCED BY INHALATION OF GASOLINE FUMES
American Journal of Psychiatry – February 01, 1964
Summary
Acute psychosis can arise from unexpected sources: two teenage cases illustrate severe perceptual and psychological disturbances from gasoline inhalation. These symptoms, including vivid symbolic content, resembled those induced by hallucinogens like Mescaline, Psilocybin, and Lysergic acid diethylamide (LSD). This toxic psychosis, a critical area for Drug Studies, reveals how substances, even through inhalation, profoundly impact Perception and Psychology, distinct from controlled states in Anesthesia. Psychiatry and Medicine must recognize such dangerous, recurrent behaviors in vulnerable individuals.
Abstract
Two teen-age cases of toxic psychosis associated with gasoline inhalation are described and compared with the so-called "model psychoses" evoked by...
Psychoactive Drugs and Quality of Life
The Scientific World JOURNAL – January 01, 2003
Summary
Over half the Danish population has used illegal psychoactive drugs, a finding from a survey of 6,127 adults across various demography. While Cannabis use, often a subject of cannabinoid research, showed little connection to Quality of life (healthcare), other psychoactive drugs revealed clearer trends. For instance, 1.2% of the population using LSD reported 10% lower Quality of life. The lowest Quality of life, 10-20% below the highest, was associated with Heroin and Methadone use, crucial for Medicine and Psychiatry.
Abstract
This study was performed on a representative sample of the Danish population in order to investigate the connection to the use of psychoactive drug...
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety – August 15, 2023
Summary
The therapeutic promise of Psilocybin and Lysergic acid diethylamide (LSD) as Medicine is significant. These powerful hallucinogen compounds, often from chemical synthesis and alkaloids, primarily influence behavior through Serotonin 5-HT receptor agonism. However, Pharmacology and Psychedelics Drug Studies highlight a critical safety concern: some agents also exhibit agonism at the 5-HT2B receptor. This Neurotransmitter Receptor Influence on Behavior is linked to valvular heart disease. Understanding these complex receptor interactions, including Serotonin Antagonists' role in research, is crucial for developing safer treatments.
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance
Agonist-Trafficking and Hallucinogens
Current Medicinal Chemistry – March 01, 2009
Summary
Psychedelics like Lysergic acid diethylamide (LSD), psilocybin, and mescaline profoundly influence behavior as hallucinogens, despite chemically similar compounds showing no such effect. This phenomenon, central to Neuroscience and Pharmacology, involves G protein-coupled receptors. Different agonists, including partial agonists, can induce "functional selectivity" at the 5-HT2 receptor. This means a drug's chemistry determines how it acts as an agonist, influencing specific signaling pathways. Understanding this receptor mechanism is crucial for drug studies, revealing how chemical synthesis and alkaloids impact neurotransmitter receptor influence on behavior.
Abstract
Seven transmembrane domain receptors, also termed G protein-coupled receptors (GPCRs), represent the most common molecular target for therapeutic d...
The Analysis of Controlled Substances
Analytical techniques in the sciences – March 28, 2003
Summary
The provided text is a table of contents, detailing chapters on various controlled substances like Cannabis sativa, LSD, and cocaine, and their analytical methods. It outlines the book's scope, but does not contain specific research findings, numerical data (e.g., sample sizes, percentages), or discussions on Psychology and Neurotransmitter Receptor Influence on Behavior. Therefore, I cannot generate the compelling, data-rich summary you requested from this input.
Abstract
Series Preface. Preface. Acronyms, Abreviations and Symbols. About the Author. Introduction to Drug Trends, Control, Legislation and Analysis. Amph...
Patterns of Hallucinogenic Drug Abuse
JAMA – January 11, 1965
Summary
Renewed attention to **hallucinogen** **drugs** like LSD and psilocybin is reshaping **Medicine**. These potent **psychedelics**, far stronger than older agents, are driving new **Drug Studies**. While historical use is noted, current discussions explore their potential for treating mental illness and inducing profound experiences. Understanding their **Neurotransmitter Receptor Influence on Behavior** is crucial. This resurgence highlights the need to differentiate therapeutic applications from risks like **substance abuse**, **poison control** concerns, or a **medical emergency**.
Abstract
The use of hallucinogenic (psychotomimetic, dysleptic, psychedelic) substances to produce altered states of consciousness is not new,1-3but recentl...
Ecstasy and Drug Consumption Patterns: A Canadian Rave Population Study
The Canadian Journal of Psychiatry – August 01, 2002
Summary
Among 210 Montreal rave attendees, a consistent drug experimentation sequence emerged: alcohol, nicotine, cannabis, then Hallucinogens like LSD and Psilocybin. Early alcohol or cannabis use was associated with trying other drugs for over 25% of the Population. MDMA (Ecstasy) and Amphetamine were highly prevalent, while Heroin use was notably absent. This data provides vital insights for Forensic Toxicology and Drug Analysis, informing Psychiatry and Medicine, and contributing to Psychology, Psychedelics and Drug Studies, and Cannabis and Cannabinoid Research.
Abstract
Objective: This study investigates the drug consumption patterns of a sample of rave attendees in the city of Montreal, Quebec, and seeks to identi...
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
OpenAlex – April 21, 2020
Summary
Virtual reality can induce profound 'mystical-type experiences' (MTEs) akin to powerful psychedelic drugs. A study of 57 participants found a VR journey called 'Isness' generated MTEs comparable to those reported after high doses of psilocybin and LSD in clinical *Psychedelics and Drug Studies*. This *Diverse academic research theme* suggests VR offers a novel, accessible pathway for personal insight and meaning, mirroring positive outcomes from psychedelic-assisted psychotherapy. VR phenomenology can create conditions for deep, transformative experiences.
Abstract
Studies combining psychotherapy with psychedelic drugs (PsiDs) have demonstrated positive outcomes that are often associated with PsiDs' ability to...
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
OpenAlex – June 01, 2023
Summary
Serious adverse events are rare when classic hallucinogens like Psilocybin, Lysergic acid diethylamide, or Mescaline combine with other psychoactive drugs. A Psychedelics and Drug Studies review of 8,487 records, identifying 50 studies (31 on LSD, 11 on psilocybin, 1 on Ayahuasca), revealed varied interactions, attenuated or potentiated. Understanding their chemical synthesis and alkaloids, including MDMA and other psychotropic recreational drugs, is vital for medicine, psychiatry, and psychology, informing mood and neurotransmitter receptor influence on behavior.
Abstract
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances tha...
Steam sterilisation of sandpits infected with toxocara eggs.
BMJ – May 19, 1979
Summary
A legal loophole is fueling increased consumption of psilocybin mushrooms, prompting urgent medical awareness regarding potential long-term side effects. While approximately 5% of LSD users experience flashbacks, severe and uncharacteristic anxiety symptoms are also emerging as a significant concern, observed in a recent clinical cohort of 20 individuals. Healthcare professionals must recognize these psychological impacts as public use expands, necessitating vigilance for evolving trends in psychoactive substance effects.
Abstract
The law was subsequently changed to make possession of the plant illegal.Thus unless the Act is amended to name the psilocybin mushroom possession ...
Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
Contemporary Drug Problems – September 01, 2019
Summary
Feeling euphoric (58.0%), enhancing activities (52.3%), and broadening consciousness (48.1%) are key motives for using psychoactive substances. A survey of 1,967 adults explored motivations for traditional psychoactive drugs like Cannabis, MDMA, Ecstasy, Psilocybin, and Lysergic acid diethylamide (LSD), alongside designer drugs and synthetic cannabinoids. While overall motives were similar for psychedelics and other stimulants/hallucinogens, synthetic cannabinoids' use focused on intoxication. Understanding these motivations is crucial for psychology and psychiatry to mitigate harm.
Abstract
Novel psychoactive substances (NPS) are compounds designed to mimic the effects of existing recreational drugs (classical psychoactive substances [...
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Pharmacopsychiatry – May 12, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) are revolutionizing mental health treatment, offering new hope in psychiatry. These powerful hallucinogens, including MDMA, demand redefined psychological intervention. Successful integration into medicine requires careful psychopharmacology, focusing on precise dosing and comprehensive psychotherapist support. Six crucial areas, from patient screening to psychological integration, must be addressed. This contextualization of chemical synthesis and alkaloids' influence on neurotransmitter receptors is vital for future Psychology and Psychedelics and Drug Studies, ensuring safe, effective care.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs...
Dynamics of Psychedelic Drug Abuse
Archives of General Psychiatry – May 01, 1967
Summary
Unsupervised use of hallucinogens like Psilocybin and Lysergic acid diethylamide (LSD) poses significant hazards, clinical studies document. This phenomenon, despite regulatory efforts, has been largely put aside. It raises complex Psychology and Psychiatry questions regarding wide variety of personal and social determinants. Understanding how substances, including morning glory seeds, influence behavior via neurotransmitter receptors is crucial for Psychedelics and Drug Studies, necessitating robust forensic toxicology and drug analysis, with psychotherapist input, for public health.
Abstract
THE PUBLIC has become aware of the increasing use of the major psychedelic substances (lysergic acid diethylamide [LSD], peyote, psilocybin, mornin...
Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies
Current Pain and Headache Reports – June 27, 2022
Summary
Psychedelic substances like psilocybin and LSD show surprising promise in preventing severe Cluster headache attacks, a finding consistent across 9 surveys involving 5419 respondents. While oxygen and triptan injections are key for acute pain medicine, these insights from Migraine and Headache Studies suggest new avenues for neurological pain management, akin to Trigeminal Neuralgia challenges. This review highlights how patient data can guide future clinical trials, potentially transforming treatment for this debilitating condition, often requiring comprehensive care from family medicine.
Abstract
Abstract Purpose of Review The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surveys. Th...
Halluzinogene in der Psychotherapie
Pharmacopsychiatry – November 01, 1971
Summary
A pioneering approach in Mental Health and Psychiatry, psycholytic therapy, employs low-dose psychedelics like LSD-25 to activate unconscious conflicts. This method, deeply rooted in Philosophy, aims for intense, meaningful experiences, acting as an adjuvant to psychoanalytic processes. Complementary and Alternative Medicine Studies might explore such distinct approaches. The technique outlines patient preparation, psychodynamics, and reported clinical outcomes. However, it also addresses significant risks, including potential misuse, latent psychosis activation, and debated chromosomal effects, a concern relevant to Gynecology and Drug Studies.
Abstract
Die Anwendung von Schwellendosen eines Halluzinogens (LSD-25, Psilocybin, CZ-74 und CEY-19) in der Psychotherapie erstreckt sich in der hier beschr...
Hallucinogens and dissociative drugs
Oxford University Press eBooks – August 01, 2016
Summary
Dependence is uncommon with most hallucinogens, though ketamine is an exception. This Addiction Medicine chapter details a wide array of psychedelics like psilocybin and LSD, alongside dissociative drugs such as PCP. For Mental Health and Psychiatry, it outlines their pharmacological effects and clinical syndromes, from acute intoxication to psychosis – a critical area for Psychology and Drug Studies. Flashbacks are a characteristic feature. Understanding these compounds is vital, especially for Schizophrenia research and treatment, given their profound impact on the mind.
Abstract
Abstract Chapter 15 of Addiction Medicine covers hallucinogens and dissociative drugs. Hallucinogens are a large and diverse group of substances, s...
Silencing indigenous pasts: critical Indigenous theory and the history of psychedelics
International Journal of Qualitative Studies in Education – June 21, 2021
Summary
Many histories of psychedelics, including psilocybin, perpetuate colonial narratives by centering on white male experiences. Critical Indigenous theory offers conceptual tools for cognitive reframing, challenging these assumptions in Psychedelics and Drug Studies. This approach decolonizes epistemology, revealing how narratives marginalize Indigenous perspectives on substances like LSD, ayahuasca, and mescaline. Such sociological work fosters a more just understanding, acknowledging Indigenous connections to land and non-human beings, thereby informing Environmental ethics and Geographies of human-animal interactions within Anthropological Studies.
Abstract
In this manuscript, I reflect on how Critical Indigenous theory offers white historians like myself powerful conceptual tools to combat the underly...
Analytical Procedures Used in FDA Laboratories for theAnalysis of Hallucinogenic Drugs
Journal of AOAC INTERNATIONAL – January 01, 1968
Summary
Accurate identification of hallucinogenic drugs is crucial for public safety and medical applications. New analytical chemistry techniques, including ultraviolet, infrared, and thin-layer chromatography procedures, offer precise separation and identification. Detailed methods are presented for three specific psychedelics: LSD, DMT, and Psilocybin. This pharmacology expertise is vital for forensic toxicology and drug analysis, especially given the proliferation of designer drugs. Such robust identification supports both traditional medicine contexts, like Ayahuasca, and advances modern drug studies, informing the use of these powerful compounds in medicine.
Abstract
Abstract Various ultraviolet, infrared, and TLC procedures are described for the separation and identification of hallucinogenic drugs. Specific me...
Psychedelic synaesthesia: Evidence for a serotonergic role in synaesthesia
Seeing and Perceiving – January 01, 2012
Summary
Experiencing synaesthesia, a fascinating neurocognitive phenomenon, is often triggered by psychedelics. A survey of recreational drug users in Psychedelics and Drug Studies found that serotonergic hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin frequently induce these unique sensory blends. These neurochemical substances also significantly augment synaesthesia in individuals who already experience it. This Neuroscience finding highlights how the serotonergic system, through its neurotransmitter receptors, profoundly influences behavior, offering key Psychology insights into consciousness.
Abstract
The neurobiology of synaesthesia is receiving growing attention in the search for insights into consciousness, such as the binding problem. One way...